In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioAssets: Convergence as Marketing Play

Executive Summary

Most drug and device companies approach convergence as a product development issue--the actual combination in a single product of both device and pharmaceutical attributes. But what if convergence were played out as part of a marketing strategy? That's one of the possibilities being explored by BioAssets, a drug company with a novel approach to the use of TNF inhibitors in spine, who hopes to tap into the strong customer relationships that spine device companies have with surgeons.

You may also be interested in...



At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?

Still feeling the reverberations of data released in Barcelona in September, this year's TCT meeting saw session after session on the risks of stent thrombosis from drug-eluting stents. While the data was clear--there is some risk, but not a lot--what to do about it was less clear. And the whole debate raises more questions than answers, for both interventionalists and cardiovascular device companies.

Spinal Concepts: Leading Abbott into the Spine Market

The success of Abbott Laboratories' acquisition of Spinal Concepts may depend as much on company restraint as on company resources.

Convergent Calling: An Interview with Medtronic's Stephen Oesterle

Historic walls between the medical device and biotech sectors are coming down as medical devices incorporate more biologically-active agents as part of their therapy. That's good news for device companies since device technology in these combination devices is every bit as critical to their clinical success as the biologic.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel